Business
Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018
Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nJoin Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nJoin Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 9, 2018\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 9, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that members of its management team will be attending the 3rd CannX Medical Cannabis Conference, to be held in the Tel Aviv Convention Centre, on October 14th – 16th  2018, and will be available for one-on-one meetings.\nThe 3rd International Medical Cannabis Conference, CannX, is an annual event for global leaders in areas of Medical Cannabis to convene, explore and present the latest scientific and clinical research in the field.\nAt the convention, Dr. Gil Bar-Sela is scheduled to present his findings of the clinical trial Cannabics completed. While briefly noted in the Company's press release of July 3rd, 2018, and September 21st, 2018; this will be the first public scientific presentation of the official results of this pilot study.\nDr. Bar-Sela has vast knowledge and experience in clinical evaluation of medical cannabis benefits to Cancer patients. Dr. Bar-Sela was the principal investigator of the company's clinical study, the first meaningful scientific study regarding the dosage and treatment regimen in oral administration of cannabis and the benefits in treating CACS in Cancer patients. \nDr. Bar-Sela's Lecture is scheduled for Monday, October 15th, 2018, and entitled \"OPENING THE GATES TO NEW CLINICAL RESEARCH.\"\nWhile this Clinical Study was conducted at Rambam Hospital in Israel, it is registered with the US NIH under \"Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer ...